Full Press Release Details
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number: 001-36697
(Translation of registrant s name into English)
Green Square-B timent D
80/84 rue des Meuniers
92220 Bagneux France
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
| Exhibit | Description | |
| 99.1 | Press Release dated June 2, 2015. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
| DBV TECHNOLOGIES S.A. | ||||||||
| Date: June 2, 2015 | By: | /s/ David Schilansky | ||||||
| Name: | David Schilansky | |||||||
| Title: | Chief Operating Officer |
Bagneux, France, June 2, 2015
Technologies to Attend Upcoming
Investor Conferences
Technologies, (Euronext: DBV ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, today announced that Susanna Mesa, Vice President of Finance, Investor Relations & Strategy, will
present and host investor meetings at the following upcoming investor conferences:
A live audio webcast of the Jefferies presentation will be available on the Investor Relations section of the Company s website,
http://www.dbv-technologies.com/en/investor-relations. A replay of the presentation will also be available on DBV s website within 48 hours after the event.
About DBV Technologies
DBV Technologies is developing
Viaskin , an innovative new approach to the treatment of allergies a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002,
has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is
focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products candidates: Viaskin Peanut and Viaskin Milk. The clinical development program for Viaskin Peanut has received Fast Track designation and Breakthrough Therapy designation from
the U.S. Food and Drug Administration.
DBV Technologies shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and on
the Nasdaq Stock Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
| DBV Technologies Contacts | ||
| Nathalie Donne Director, Corporate Communication & Business Development T l. : +33(0)1 55 42 78 72 nathalie.donne@dbv-technologies.com | Susanna Mesa VP Finance, US Investor Relations & Strategy T l. : +1 917-346-3447 susanna.mesa@dbv-technologies.com | |
| DBV Technologies Media Contacts | ||
| Marion Janic Rooney & Associates T l. : +1-212-223-4017 mjanic@rooneyco.com |